Sleep Apnea and Chronic Inflammation: Why Disrupted Breathing Inflames Your Body

Obstructive sleep apnea (OSA) affects an estimated 1 billion people worldwide, making it one of the most prevalent sleep disorders and one of the most underdiagnosed. Characterized by repeated episodes of upper airway collapse during sleep, OSA produces cycles of oxygen desaturation and reoxygenation throughout the night that activate a specific form of inflammatory stress called intermittent hypoxia (IH). This IH-driven inflammation is distinct from and additive to the inflammation caused by sleep fragmentation alone, and it explains much of the dramatically elevated cardiovascular and metabolic disease risk associated with untreated OSA.

Unlike continuous hypoxia, which activates adaptive responses, intermittent hypoxia is particularly damaging because each reoxygenation episode generates a burst of reactive oxygen species (ROS) in a pattern resembling ischemia-reperfusion injury. This repeated oxidative insult activates NF-kB and the downstream inflammatory cascade with each oxygen cycle, producing a pattern of chronic immune activation that persists even during waking hours.

Intermittent Hypoxia and Inflammatory Signaling

Each apnea event, when breathing stops for 10 to 60 seconds or longer, causes blood oxygen saturation to drop, sometimes significantly. When breathing resumes, oxygen floods back into tissues. This ischemia-reperfusion cycle generates a burst of reactive oxygen species from mitochondria and NADPH oxidase in endothelial cells and macrophages. ROS activate NF-kB, leading to transcription of TNF-alpha, IL-6, IL-8, and other pro-inflammatory cytokines. The more severe the apnea (measured as apnea-hypopnea index, or AHI), the more cycles of hypoxia-reoxygenation occur per night, and the greater the cumulative inflammatory activation.

Intermittent hypoxia also activates hypoxia-inducible factor 1-alpha (HIF-1alpha), a transcription factor that upregulates genes promoting VEGF (vascular endothelial growth factor), erythropoietin, and additional inflammatory mediators. HIF-1alpha activation promotes monocyte and macrophage activation in a pattern that drives atherosclerotic plaque development and destabilization. Studies have found that apnea severity correlates directly with circulating levels of activated monocytes and adhesion molecules on endothelial cells, the early steps in plaque formation.

OSA and Cardiovascular Inflammatory Risk

The cardiovascular disease burden associated with untreated OSA is substantial and largely mediated by inflammation. Multiple large cohort studies have found that individuals with moderate to severe OSA have significantly elevated CRP, IL-6, and fibrinogen compared to matched controls, after controlling for obesity and other confounders. A study in the journal Chest found that OSA severity was independently associated with CRP elevation, with each additional unit increase in AHI predicting a proportional increase in CRP after adjustment for BMI.

OSA is associated with a two- to three-fold increase in hypertension, a two-fold increase in atrial fibrillation, and significantly elevated rates of myocardial infarction and stroke. The inflammatory endothelial activation, platelet hyperreactivity, and oxidative stress produced by intermittent hypoxia provide mechanistic explanations for each of these associations. Importantly, the elevated cardiovascular risk in OSA patients persists even after adjusting for obesity, suggesting that the hypoxia-driven inflammation contributes to risk independently of the adiposity that commonly accompanies OSA.

Metabolic Consequences: Insulin Resistance and Visceral Fat

OSA-driven inflammation also disrupts metabolic function. Intermittent hypoxia impairs insulin signaling in adipose tissue and skeletal muscle, worsening insulin resistance independently of body weight. The inflammatory cytokines produced during nocturnal hypoxia episodes elevate cortisol and catecholamines that persist into waking hours, promoting visceral fat accumulation and further exacerbating insulin resistance. Studies consistently show that individuals with OSA have worse insulin sensitivity than BMI-matched controls, and that OSA treatment improves insulin sensitivity independently of weight change.

The bidirectional relationship between OSA and metabolic disease creates a harmful feedback loop. Obesity promotes OSA by increasing pharyngeal fat deposition that collapses the airway during sleep. OSA then promotes the metabolic inflammation that drives further weight gain and insulin resistance, making the OSA harder to treat. This cycle partially explains why metabolic syndrome is so prevalent in OSA patients and why treating the apnea alone, without addressing lifestyle factors, often produces incomplete metabolic improvement.

Treatment Effects on Inflammatory Markers

Continuous positive airway pressure (CPAP) therapy, the standard treatment for moderate to severe OSA, effectively eliminates apnea events and the intermittent hypoxia they produce. Clinical trials examining CPAP's effects on inflammatory markers have found significant reductions in CRP, IL-6, and TNF-alpha with adequate treatment adherence (typically defined as more than 4 hours per night). A 2019 meta-analysis of 18 randomized trials found that CPAP reduced CRP by 0.6 to 1.2 mg/L in patients with elevated baseline levels, an effect size comparable to moderate aerobic exercise.

The degree of inflammatory improvement correlates with treatment adherence. Patients using CPAP for more than 6 hours per night show significantly greater CRP reductions than those using it for fewer hours. For individuals who cannot tolerate CPAP, alternative treatments including oral appliances and positional therapy reduce AHI and also produce anti-inflammatory effects, though typically of smaller magnitude for severe OSA. Given that OSA is profoundly underdiagnosed, overnight sleep testing or home sleep apnea testing is worth considering for individuals with unexplained elevated CRP, daytime fatigue, snoring, or reported breathing pauses during sleep.